-

Mitsubishi International Food Ingredients, Inc. ("MIFI") Rebrands Fine Chemicals Department as MIFI Bioceuticals™ to Support Strategic Growth

HACKENSACK, N.J.--(BUSINESS WIRE)--Mitsubishi International Food Ingredients, Inc. ("MIFI") announced today the upcoming rebranding launch of its legacy Fine Chemicals Department as "MIFI Bioceuticals™," effective December 1, 2022, homing in on the building and advancing a portfolio of unique pharmaceutical, biochemical, cosmetic, and other fine chemical ingredients.

The timing of its new MIFI Bioceuticals brand launch aligns with the business transformation that is taking place across MIFI with a fresh- and forward-looking approach to the market.

This news comes in the wake of many recent initiatives and accomplishments of the organization, including:

  • Launching innovative synthetic peptide growth factors from PeptiGrowth can be a game changer in manufacturing cell therapy, regenerative medicine, and cultivated meat products. Unlike conventional growth factors and cytokines, synthetic peptide growth factors are completely chemically defined and can achieve consistent quality without batch-to-batch variation or contamination with biological impurities and higher stability in cell culture media while lowering costs.
  • Innovative sunscreen formulation development utilizing its Micro Titanium Dioxide and Micro Zinc Oxide product lines, providing solutions to challenges of sunscreen formulations using Titanium Dioxide and Zinc Oxide.
  • The launch of the world's first cosmetic ingredient with Aza-Oxohypoxanthine, Repista, from VC60 BioResearch Corporation, following its original product line of Plant-based Fullerene.

"The markets of biopharmaceutical, pharmaceutical, cosmetic, and other fine chemical ingredients are constantly pivoting and innovating, as are we. The new brand, MIFI Bioceuticals™, is just the start of our new chapter as a true solutions provider in related industries," Tomoaki Masuda, President of MIFI Bioceuticals, states. "We will continue to evaluate and elevate our product portfolio and services to better support customers' innovations. We will be launching a new website specifically for MIFI Bioceuticals™ in early 2023. In the interim, please visit us at mifiusa.com and use the contact information below to reach the MIFI Bioceuticals™ team."

About MIFI Bioceuticals
As a global supply chain partner, Mitsubishi International Food Ingredients, Inc. ("MIFI") focuses on achieving excellence in sourcing and distributing food, nutritional, pharmaceutical, and cosmetic ingredients. MIFI Bioceuticals™ is the new name division of MIFI's Fine Chemicals Department, specifically engaging in pharmaceuticals, cosmetics, and other fine chemicals businesses. MIFI Bioceuticals vision is to "be a solution provider with unique & innovative ingredients," focusing on differentiated products and services with clear competitive advantages.

Contacts

For further information, please contact:
Tomoaki Masuda, President
MIFI Bioceuticals™, a division of Mitsubishi International Food Ingredients, Inc.
(201) 242-5104
team@mifibioceuticals.com
Contact us on mifiusa.com
Follow us on LinkedIn

Mitsubishi International Food Ingredients, Inc


Release Summary
Mitsubishi Ingredients launches the rebrand of Fine Chem Dept to MIFI Bioceuticals: advancing portfolio advancement of pharma, biochem, cosmetic, etc.
Release Versions

Contacts

For further information, please contact:
Tomoaki Masuda, President
MIFI Bioceuticals™, a division of Mitsubishi International Food Ingredients, Inc.
(201) 242-5104
team@mifibioceuticals.com
Contact us on mifiusa.com
Follow us on LinkedIn

Social Media Profiles
More News From Mitsubishi International Food Ingredients, Inc

PeptiGrowth Inc. Is Launching A Novel Synthetic Peptide TGFβ1 Inhibitor, Following Its First Product HGF Alternative Peptide

TOKYO--(BUSINESS WIRE)--PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel peptide called TGFβ1 inhibitor (TGFβ1 binding peptide) which binds to TGFβ1 to inhibit its activity. Development of Synthetic Peptide Growth Factors by PeptiGrowth Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variation, potential co...
Back to Newsroom